FDA rejects Akcea rare-disease drug that uses gene-blocking technology

FDA rejects Akcea rare-disease drug that uses gene-blocking technology

Source: 
Stat
snippet: 

The Food and Drug Administration on Monday rejected Akcea Therapeutics’ application to market Waylivra, its drug for familial chylomicronemia syndrome, in the United States.